Pharminent

5 trends shaping Alzheimer’s drug development

Almost all Alzheimer’s drugs have failed. But pharma continues to invest millions in hopes of finding a hit, motivated by market opportunity and armed with lessons learned. http://www.biopharmadive.com/news/alzheimers-disease-trends-drug-development-amyloid-biomarkers/447068/

Filed under: Alzheimer’s

Alzheon says data backs potential of Alzheimer’s candidate

US biotech points to new analysis of phase III results for tramiprosate http://www.pmlive.com/pharma_news/alzheon_says_data_backs_potential_of_alzheimers_candidate_1196981

Filed under: Alzheimer’s

Merck licenses Teijin Pharma’s Alzheimer’s candidate

Merck has signed a worldwide license agreement with Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical antibody candidate targeting the protein tau. http://drugdiscovery.pharmaceutical-business-review.com/news/merck-tejin-sign-license-agreement-for-tau-targeting-antibody-260517-5825579

Filed under: Alzheimer’s

Alzheimer’s experts call for changes in FDA drug approval standards

Leading Alzheimer’s disease researchers and a prominent patient advocate today published an analysis, “Single Endpoint for New Drug Approvals for Alzheimer’s Disease," urging the Food and Drug Administration (FDA) to clarify and modernize its current approach for approving new treatments for Alzheimer’s disease. http://www.worldpharmanews.com/development/3931-alzheimer-s-experts-call-for-changes-in-fda-drug-approval-standards

Filed under: Alzheimer’s

Cytox Plans US Clinical Launch for Early-Stage Alzheimer’s Test While Courting Pharma Partners

https://www.genomeweb.com/molecular-diagnostics/cytox-plans-us-clinical-launch-early-stage-alzheimers-test-while-courting

Filed under: Alzheimer’s

FDA authorizes first direct-to-consumer genetic test panel for predisposition to Alzheimer’s disease and other serious disorders

The FDA has announced its decision to grant a de novo application submitted by 23andMe for the company’s direct-to-consumer (DTC) Personal Genome Service Genetic Health Risk (“GHR") tests. The GHR test panel currently includes genetic variants…By: DLA Piper http://www.jdsupra.com/legalnews/fda-authorizes-first-direct-to-consumer-40610/

Filed under: Alzheimer’s

Genentech plans second Phase 3 Alzheimer’s trial following endpoint failures

Genentech, Roche’s biotech group, has announced its plans to conduct a second Phase 3 study for crenezumab, its anti-Abeta antibody for the treatment of early Alzheimer’s disease.
The trial is designed to further elucidate earlier traces data on the drug’s efficacy in treating Alzheimer’s; crenezumab failed to meet its primary endpoint of slowing cognitive degeneration in mild-to-moderate forms of the disease in two 2014 Phase 2 studies, but did show promise as a treatment in the earliest stages.
read more http://www.pharmafile.com/news/513609/genentech-plans-second-phase-3-alzheimers-trial-following-endpoint-failures

Filed under: Alzheimer’s

Roche to start new trial of AC Immune drug against Alzheimer’s

http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/roche-start-trial-ac-immune-081559986.html

Filed under: Alzheimer’s

AbbVie takes anti-tau drug into phase II for Alzheimer’s

Also testing
antibody in rare condition PSP, for which FDA has awarded
fast-track designation http://www.pmlive.com/pharma_news/abbvie_takes_anti-tau_drug_into_phase_ii_for_alzheimers_1185122

Filed under: Alzheimer’s

Lilly and AstraZeneca to Develop Second Potentially Disease-Modifying Treatment for Alzheimer’s Disease

INDIANAPOLIS, Dec. 9, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and AstraZeneca announced a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which is currently in Phase 1 trials as a potential disease-modifying treatment for… http://www.prnewswire.com/news-releases/lilly-and-astrazeneca-to-develop-second-potentially-disease-modifying-treatment-for-alzheimers-disease-300375924.html

Filed under: Alzheimer’s

Amyloid Also Accumulates In Heart In Alzheimer’s (CME/CE)

(MedPage Today) — Small study shows heart function affected, too http://www.medpagetoday.com/Cardiology/CHF/61708

Filed under: Alzheimer’s

Roche confident in Alzheimer’s programmes, despite Lilly flop

http://finance.yahoo.com/news/roche-confident-alzheimers-programmes-despite-203033118.html

Filed under: Alzheimer’s

Study Challenges Model of Alzheimer’s Disease Progression

NewsAlzheimer’s disease is a neurodegenerative disorder for which, despite years of research, there are no effective treatments or cures.Contributed Author: Cornell UniversityTopics: Disease Research http://www.dddmag.com/news/2016/11/study-challenges-model-alzheimers-disease-progression

Filed under: Alzheimer’s

Gene Therapy Shows Early Signs of Preventing Alzheimer’s Disease

ArticleThe findings suggest that this therapy would be most effective in the early stages of disease.Staff Author: Ryan BusheyTopics: Biotech http://www.dddmag.com/article/2016/10/gene-therapy-shows-early-signs-preventing-alzheimers-disease

Filed under: Alzheimer’s

Computer Simulations Explore How Alzheimer’s Disease Starts

NewsUsing computer simulations to explore the initial steps of the molecular process that leads to Alzheimer’s disease.Contributed Author: Rice UniversityTopics: Disease Research http://www.dddmag.com/news/2016/10/computer-simulations-explore-how-alzheimers-disease-starts

Filed under: Alzheimer’s

Allergan, Adamas introduce new Namzaric dosage strengths in US to treat Alzheimer’s disease

Allergan plc, a leading global pharmaceutical company, and Adamas Pharmaceuticals, Inc. announced that all four dosage strengths of Namzaric (memantine and donepezil hydrochlorides) extended─release http://pharmabiz.com/ArticleDetails.aspx?aid=97652&sid=2

Filed under: Alzheimer’s

Biogen’s Alzheimer’s Therapy Granted FDA Fast-Track Status

http://www.wsj.com/articles/biogens-alzheimers-therapy-granted-fda-fast-track-status-1472769993

Filed under: Alzheimer’s

Lilly and AstraZeneca Receive FDA Fast Track Designation for AZD3293, an Investigational Treatment for Early Alzheimer’s Disease

INDIANAPOLIS, Aug. 22, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and AstraZeneca today announced they have received U.S. Food and Drug Administration (FDA) Fast Track designation for the development program in Alzheimer’s disease for AZD3293, an oral beta secretase cleaving… http://www.prnewswire.com/news-releases/lilly-and-astrazeneca-receive-fda-fast-track-designation-for-azd3293-an-investigational-treatment-for-early-alzheimers-disease-300315784.html

Filed under: Alzheimer’s

Eisai: FDA confirms enough data to move Alzheimer’s drug to Phase III studies

TOKYO (Reuters) – Japan’s Eisai Co said on Tuesday the U.S. Food and Drug Administration had confirmed that there was sufficient data to start Phase III studies of a drug it is co-developing to treat early Alzheimer’s disease.
http://www.reuters.com/article/us-eisai-biogen-alzheimers-idUSKCN10K0LX

Filed under: Alzheimer’s

New Biochip-Based Blood Test Detects Elevated Risk for Alzheimer’s Disease

PHILADELPHIA, Aug. 3, 2016 /PRNewswire-USNewswire/ — Researchers today unveiled results from a new blood test to help identify which patients are at an elevated risk of Alzheimer’s disease. The findings, presented at the 68th AACC Annual Scientific Meeting & Clinical Lab Expo in… http://www.prnewswire.com/news-releases/new-biochip-based-blood-test-detects-elevated-risk-for-alzheimers-disease-300308429.html

Filed under: Alzheimer’s

Categories